Show simple item record

dc.contributor.authorKent, T
dc.contributor.authorCaunter, A
dc.contributor.authorTrott, J
dc.contributor.authorWilliams, CA
dc.contributor.authorEnderby, B
dc.contributor.authorWithers, NJ
dc.contributor.authorTomlinson, OW
dc.date.accessioned2022-06-22T12:09:14Z
dc.date.issued2022-06-01
dc.date.updated2022-06-21T15:36:56Z
dc.format.extents123-
dc.identifier.citationVol. 21, p. s123en_GB
dc.identifier.doihttps://doi.org/10.1016/s1569-1993(22)00534-3
dc.identifier.urihttp://hdl.handle.net/10871/130018
dc.identifierORCID: 0000-0003-4063-7682 (Tomlinson, OW)
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.rights.embargoreasonUnder embargo until 1 June 2023 in compliance with publisher policyen_GB
dc.rights© 2022. This version is made available under the CC-BY-NC-ND 4.0 license: https://creativecommons.org/licenses/by-nc-nd/4.0/  en_GB
dc.titleKaftrio® improves VO2max in patients with cystic fibrosisen_GB
dc.typeArticleen_GB
dc.date.available2022-06-22T12:09:14Z
dc.identifier.issn1569-1993
dc.descriptionThis is the author accepted manuscript. The final version is available from Elsevier via the DOI in this recorden_GB
dc.identifier.journalJournal of Cystic Fibrosisen_GB
dc.relation.ispartofJournal of Cystic Fibrosis, 21
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_GB
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2022-06-01
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2022-06-22T12:06:58Z
refterms.versionFCDAM
refterms.dateFOA2023-05-31T23:00:00Z
refterms.panelAen_GB
refterms.dateFirstOnline2022-06-01


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2022. This version is made available under the CC-BY-NC-ND 4.0 license: https://creativecommons.org/licenses/by-nc-nd/4.0/  
Except where otherwise noted, this item's licence is described as © 2022. This version is made available under the CC-BY-NC-ND 4.0 license: https://creativecommons.org/licenses/by-nc-nd/4.0/